21/11/2025
New guidance from NICE (the National Institute for Health and Care Excellence) gives another treatment option for people with hormone-sensitive metastatic prostate cancer for whom docetaxel is not suitable.
The guidance discusses the use of darolutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer.
https://www.ucc-today.com/journals/issue/launch-edition/article/treating-hormone-sensitive-metastatic-prostate-cancer-new-nice-guidance